Please ensure Javascript is enabled for purposes of website accessibility

Why Novavax Stock Is Rising Today

By Keith Speights - May 24, 2021 at 11:13AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech signed a memorandum of understanding that could increase its opportunity in South Korea.

What happened

Shares of Novavax (NVAX -5.56%) were rising 3.4% higher as of noon EDT Monday after jumping as much as 5.7% earlier in the day. The bump appeared to stem from Novavax's announcement on Saturday that it signed a memorandum of understanding (MoU) to "explore the expansion of COVID-19 vaccine activities in South Korea."

So what

This MoU was signed by Novavax, the Ministry of Health and Welfare of Korea (MOHW), and SK Bioscience. Novavax and SK are already working together to target the South Korean market with Novavax's COVID-19 vaccine candidate, NVX-CoV2373. The new MoU focuses on the potential development of COVID-19 variant vaccines and/or a combo flu/COVID-19 vaccine.

Healthcare professional holding a COVID-19 vaccine vial while giving a thumb up

Image source: Getty Images.

Why didn't the biotech stock move even higher on this news? Probably because of the somewhat tentative nature of the MoU. First of all, an MoU isn't an ironclad contract between parties. Novavax stated that the MoU was non-binding. There were also some relatively wishy-washy words used -- for example, Novavax and SK bioscience agreed to "potentially explore" developing new vaccine products. 

Nonetheless, it's good news for Novavax that its opportunities in South Korea might expand. The signing ceremony for the MoU held over the weekend underscores that Novavax and SK bioscience are in a position to be major players in the country's COVID-19 vaccine market.

Now what

The big hurdle for Novavax is still to secure authorization for NVX-CoV2373. SK Bioscience began a rolling submission for the experimental vaccine to South Korean regulators in April. Novavax recently announced that it plans to file for Emergency Use Authorizations in the U.S., U.K., and Europe in the third quarter of this year.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
$37.18 (-5.56%) $-2.19

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.